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Abstract 
Following the SARS-CoV-2 pandemic, numerous serological tests have been 
developed, including rapid diagnostic tests. This study aims at assessing the clinical 
performance of the Panbio IgG/IgM COVID-19 test (Abbott), a rapid lateral flow 
assay for the qualitative detection of IgG and IgM against SARS-CoV-2. One hundred 
and thirty-eight samples from 95 COVID-19 patients with a positive SARS-CoV-2 
RT-PCR were analyzed to assess the clinical sensitivity. Seventy-six pre-COVID-19 
samples were used to evaluate the clinical specificity. Two independent and blinded 
raters determined visually the presence or absence of the IgG, IgM and control lines 
for each test after 10 and 20 minutes. The sensitivity obtained with samples collected 
more than 14 days after the onset of symptoms was 95.2% for IgG. IgM were less 
frequently detected (highest sensitivity of 20.5%). The specificities obtained were 
98.7% and 100% and for IgG and IgM respectively. In addition, the sensitivity of the 
assay was better when the reading was performed at 20 minutes than at 10 minutes, 
whereas the specificity was unchanged. The Panbio COVID-19 IgG/IgM rapid test 
 











presents high sensitivities for IgG 14 days since symptom onset but a low sensitivity 
for IgM. The specificity was excellent for both IgG and IgM. 
*these authors contributed equally. 
Introduction 
Rapid tests are designed for use where a preliminary screening test result is required 
and are especially useful in resource-limited countries or for broad screening 
campaign where access to blood sampling may be difficult or not obligatory. 
However, these tests have to be of high quality, user-friendly, quick and easy to 
perform and they have to require little or no additional equipment. In the context of 
COVID-19, all the above-mentioned criteria are of importance as serological tests 
may be useful for the diagnosis, for the characterization of the course of the disease, 
for identifying convalescent plasma donors directly on site, for lockdown exit 
programs, for epidemiological study and for the assessment of COVID-19 vaccine 
response 1. Due to their widespread dissemination and the limited experience with 
these assays, it is crucial for laboratories to rigorously validate these methods before 
broad introduction into routine clinical practice. This study aims at evaluating the 
clinical performances of the Panbio COVID-19 IgM/IgG rapid test (Abbott, Chicago, 
United States) in a population of COVID-19 patients. 
Materials and Methods 
Sample Collection 
This study was conducted from June 16, 2020, to June 24, 2020. Blood samples were 
collected from patients into serum-gel tubes (BD Vacutainer® 8.5 mL tubes, Becton 
Dickinson, New Jersey, USA) or lithium heparin plasma tubes (BD Vacutainer® 4.0 
mL tubes) according to standardized operating procedure and manufacturer 
 











recommendations. Samples were centrifuged for 10 minutes at 1,885 to 2,500 × g 
(ACU Modular® Pre Analytics, Roche Diagnostics®). A total of 214 samples were 
collected from April, 2019 to May 25, 2020, and stored in the laboratory biobank at -
20°C. Pre-COVID-19 samples (n = 76) were all collected before March 2020, the 
start of the pandemic in Belgium. One hundred and thirty-eight samples from 95 
COVID-19 patients were collected between March 21, 2020, and May 25, 2020. 
Frozen samples were thawed at room temperature. The study fulfilled the ethical 
principles of the Declaration of Helsinki. 
Analytical Procedures 
The Panbio IgG/IgM COVID-19 rapid test (Abbott) is a rapid lateral flow assay 
(LFA) for the qualitative detection of IgG and IgM directed against SARS-CoV-2 in 
human whole blood, serum or plasma specimens. The Panbio test was performed 
according to the manufacturer’s instruction for use. Briefly, 10 µL of sample were 
applied into the specimen well and then two drops of buffer were applied. Raters 
determined visually the presence or absence of the IgG, IgM and control lines for 
each test 10 and 20 minutes after the addition of the buffer. As recommended by the 
manufacturer, even a slight colored striped was considered positive. 
The reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 
determination in respiratory samples (nasopharyngeal swab samples) was performed 
on the LightCycler® 480 Instrument II (Roche Diagnostics®) using the LightMix® 
Modular SARS-CoV E-gene set. 
Assessment of the Clinical Sensitivity 
Samples (n=138) obtained from 95 patients with a confirmed RT-PCR SARS-CoV-2 
diagnosis were assessed to determine the clinical sensitivity of the assay. Sensitivity 
 











was defined as the proportion of correctly identified COVID-19 positive patients 
since symptom onset. Antibody kinetics was evaluated using all samples dividing in 
different categories based on the number of days after the symptom onset, as follows: 
0-2 days (n=15); 3-5 days (n=6); 6-8 days (n=14); 9-11 days (n=9): 12-14 days 
(n=11): 15-17 days (n=13); 18-21 days (n=13); 22-25 days (n=15); 26-31 days 
(n=13); 32-40 days (n=12) and more than 40 days (n=17). 
Assessment of the Clinical Specificity 
Non-SARS-CoV-2 samples (n=76) collected prior to the COVID-19 pandemic 
(between April and June 2019) with potential cross-reactions (n=38) were also 
analyzed to assess the specificity. Samples included positive antinuclear antibodies 
(n=4), anti-thyroglobulin antibody (n=1), anti-Treponema pallidum antibodies (n=1), 
anti-TPO antibodies (n=3), direct coombs (n=1), hepatitis B Ag (n=3), IgA 
Chlamydia pneumoniae (n=1), IgG Chlamydia trachomatis (n=1), IgM Borrelia 
burgdorferi (n=1), IgM Cytomegalovirus (n=4), IgM Mycoplasma pneumoniae (n=1), 
IgM Parvovirus B19 (n=1), IgM Toxoplasma gondii (n=6), IgG polyclonal activation 
(n=1), IgM and IgG polyclonal activation (n=1), search for irregular agglutinins 
(n=5), rheumatoid factor (n=1), urinary infection with Escherichia coli (n=1), urinary 
infection with Klebsiella oxytoca (n=1), and samples from 38 healthy volunteers were 
included for the specificity calculation. Specificity was defined as the proportion of 
naïve patients classified as negative. 
Evaluation of Reading Conditions 
Two independent and blinded raters determined visually the presence or absence of 
the IgG, IgM and control lines for each test after 10 and 20 minutes. In case of 
discrepancies, a third blinded and independent rater checked the presence or absence 
 











of the lines. Consensus results between all raters were used. The intra-rater (10 
minutes versus 20 minutes) and the inter-rater (rater 1 versus rater 2) concordances 
were determined.  
Statistical Analysis 
Data analysis was performed using GraphPad Prism® software (version 8.2.1, 
California, USA) and MedCalc® software (version 14.8.1, Ostend, Belgium). 
Confidence intervals for sensitivity and specificity were "exact" Clopper-Pearson 




All the tests (n=214) were valid (i.e. the control line was visible). Kinetics of the 
sensitivity of the Panbio assay to detect IgG and IgM since the onset of the first 
symptoms is described in the Figure 1. After 14 days since symptom onset, the 
Panbio assay detected IgG in 95.2% (95% CI 88.1-98.7%). Before 14 days since first 
symptoms, sensitivities were not high enough to be reliably used in clinical practice 
(50.9%, 95% CI 37.1-64.7%). 
Immunoglobulin M were less frequently detected by the Panbio assay, with 
sensitivities of 7.3% (95% CI 2.0-17.6%) and 20.5% (95% CI 12.4-30.8%) for 
samples the first 14 days and for those obtained more than 14 days since symptom 
onset respectively. The highest sensitivity for IgM obtained in a particular category 
based on the number of days after the symptom onset was 30.8% (95% CI 9.1-61.4%) 
(Figure 1). 
 











Only one sample was positive for IgM and negative for IgG. This sample was 
collected 22 days after the first symptoms. The sensitivity of the Panbio assay to 
detect IgM and/or IgG within the first 14 days since symptom onset was unchanged 
compared to the sensitivity to detect IgG (50.9%; 95% CI 37.1-64.7%). After 14 days 
since symptom onset, the Panbio assay detected IgG and/or IgM in 96.4% (95% CI 
89.8-99.3%) of samples. 
Among the 76 samples collected before the COVID-19 pandemic, only one sample 
from a healthy volunteer gave a false positive result with IgG. Samples with potential 
cross-reaction gave no false positive result. The specificity was 98.7% (95% CI 92.9-
100.0%) and 100% for IgG and IgM respectively. 
Evaluation of Reading Conditions 
The inter-rater variability was excellent when the tests were read at 10 minutes and 20 
minutes for both IgG (Cohen’s kappa coefficient at 10 minutes and 20 minutes were 
0.972 and 0.991 respectively) and IgM (Cohen’s kappa coefficient at 10 minutes and 
20 minutes were 0.945 and 0.974). In addition, the sensitivity of the assay was better 
when the reading was performed at 20 minutes than at 10 minutes (Table 1), whereas 
the specificity was unchanged. Cohen’s kappa coefficients for the different time of 
reading were lower for IgM than IgG, indicating that the time of reading influence 
more IgM results than IgG (Table 1). The positive lines (IgM and IgG) read at 10 
minutes were always positive at 20 minutes. 
Discussion 
The detection of anti-SARS-CoV-2 antibodies represents an additional method for the 
diagnosis of COVID-19 which may significantly improve the sensitivity of 
pathogenic diagnosis for COVID-19 when combined with RT-PCR 7. A wide range of 
 











assays have been developed including ELISA, CLIA, ECLIA and rapid tests 8-13. The 
main advantage of rapid diagnostic tests is that they do not require specific equipment 
and are easy to use. Furthermore, these tests are rapid, and they can be easily 
implemented in a low-resource laboratory.  
The World Health Organisation (WHO) encourages laboratories to perform 
independent assay validation, in particular regarding the clinical utilization of rapid 
device 15. Based on the conclusions of the study of the Frederick National Laboratory 
for Cancer Research (FNLCR), a Federally Funded Research and Development 
Center (FFRDC) sponsored by the National Cancer Institute (NCI), the FDA 
concluded that a list of 65 serological assays should not be distributed 16. External 
validations of these tests are therefore paramount, and a plenty of data are arriving in 
the literature 8-13,17-21. Given the leading position of Abbott for COVID-19 testing, 
independent external validation of their assays is mandatory to ensure the 
performance are in line with their claims. 
In our evaluation, the sensitivity obtained for all samples collected more than 14 days 
after the onset of symptoms was 95.2% for IgG. The Panbio assay showed weak 
sensitivity for IgM (Figure 1). The specificities obtained were 98.7% and 100% and 
for IgG and IgM respectively. In the instructions for use, Abbott Diagnostics 
mentioned a sensitivity and a specificity of 95.8% and 94.0%, respectively 22. In the 
manufacturer’s study, 48 samples of PCR confirmed patients and 50 pre-COVID-19 
samples were analyzed. Taken apart, IgG had a sensitivity and a specificity of 95.8% 
and 100% and IgM a sensitivity and a specificity of 56.3% and 94% 22. Our results are 
in agreement with these claims and we even obtained a better specificity for IgM 
although the sensitivity was lower than claimed. However, in the information 
provided by the manufacturer, the details of the studied populations were lacking, i.e. 
 











timing between symptom onset or since PCR positivity and the blood sampling as 
well as the characteristics of samples included for specificity calculation 22. 
As observed on other assays and platforms, i.e. LFA, ELISA, CLIA, ECLIA 8,18,23,24, 
we found that sensitivities before 14 days since symptom onset were not sufficient to 
be reliably used in clinical practice. We therefore recommend obtaining a control or 
confirmatory sample after 14 days to increase the detection rate of possible past-
COVID-19 infection. 
Comparing the clinical performance of these rapid tests is hazardous. Indeed, the 
design of studies vary widely across studies, i.e. number of positive and negative 
samples, the definition of negative samples, number of days since symptoms or since 
PCR positivity, comparison to a neutralization test. Some studies included only a very 
limited number of patients 20, included control samples collected during the pandemic 
period 10,21, defined different categories since symptom onset (i.e. < or > 7 days 19, 0-
6, 7-13, 14-25 days 18, or 5-9, 10-18 days 20), or different categories since RT-PCR 
positivity 20. Moreover, as with other rapid LFA 25, we showed that the result may 
depend on the reader and on the timing of reading (20 minutes better than 10 
minutes). The utilization of an automated reader may be useful to decrease the inter-
individual variation, especially when the colored stripe appears very thin. 
Conclusions 
The Panbio COVID-19 IgM/IgG rapid test presents high sensitivities for IgG 14 days 
since symptom onset but a very low sensitivity for IgM. The specificity was excellent 
for both IgG and IgM. Further investigations designed to evaluate the clinical 
performances of Panbio over a longer period of time is needed to further consider its 
use in seroprevalence studies. 
 












The data used to support the findings of this study are available from the 
corresponding author upon request. 
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Figure legend 
 
Figure 1: Kinetics of the sensitivity of the Panbio assay since the onset of 
symptoms. 
A. Kinetics of the sensitivity of the Panbio assay since the onset of first symptoms to 
detects IgG (blue dots), IgM (green triangle), and IgG and/or IgM (yellow squares). 
 











The result of each test was determined visually after 20 minutes by two independent 
and blinded operators. B. Sensitivities of the Panbio assay for IgG, IgM, and IgG 
and/or IgM since the onset of first symptoms. 
Table 1: Evaluation of the impact of the rater and the time of reading on the IgG 
(A) and IgM (B) test results. 
A. 




Reading after 10 
min 















between raters 0.972 0.991  
B. 
 Number of samples read positive for IgM / total number of samples κ coefficient 
between 
reading time  Reading after 10 min 















between raters 0.945 0.974  
 
